top of page

NCT-0513-2582

A randomized, double-blind, phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic HER2 breast cancer (HER2CLIMB-05)


Breast cancer is a disease where cells in the breast grow too much and can spread to other parts of the body. There are different kinds of breast cancer. One kind is called HER-2 positive breast cancer. HER-2 positive breast cancers tend to grow and spread faster than other kinds, but they also respond well to certain medicines. There's a research study called HER2CLIMB-05 that wants to figure out if a medicine called tucatinib, when used together with other medicines called trastuzumab and pertuzumab, can help people with HER-2 positive breast cancer that has spread to other parts of the body. This study is like a big experiment where some people will get tucatinib along with the other medicines, and some will get a placebo along with the other medicines. The researchers won't know who is getting which medicine, and the people in the study won't know either. The goal of this study is to find out if using tucatinib can make the situation better for people with HER-2 positive breast cancer that has spread.

HER-2 Positive: It is a type of breast cancer where cancer cells have higher-than-normal levels of HER-2 receptors are called HER-2 positive. These receptors are like tiny doorways on the surface of the cells. HER-2 positive breast cancers tend to grow and spread faster than other kinds, but they also respond well to certain drugs that target the HER-2 receptor.

Placebo: A placebo is a substance or treatment that has no active medical properties but is given to a patient as if it were a real medication or treatment. It is often used in medical research to compare the effects of a new drug or treatment with the effects of no treatment at all. The idea is to see if the new drug or treatment is genuinely effective by comparing how patients who receive the real treatment fare compared to those who receive the placebo

For more information about the trial, click the link below:

NCT-0513-2582

Clinical Trial Site: Einstein


To see all available clinical trials click here.



Recent Posts

See All

NCI-2023-06503

An open-label, single-arm, Phase 1b/2 study to investigate the safety, efficacy and pharmacokinetics of LS301-IT in female patients undergoing partial mastectomy and sentinel lymph node biopsy (SLNB)

NCI-2022-02453

A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer Doctors are conducting a study to test the safety and effectiveness of a new medicine called

NCI-2022-07265

EAY191-N2 Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1 A ComboMATC

bottom of page